Exit
Before you view this Tweetorial, please take this pre-assessment. Taking this pre-assessment does not immediately qualify learners to earn credit. 

Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit.

Question Title

* 1. What are your credentials?

Question Title

* 2. What is your community of practice?

Question Title

* 3. What is your specialty?

Question Title

* 4. Based on the MAMMOTH & LocoMMotion study, which of following best characterizes the median OS (in months) of patients w/ multiple myeloma refractory to a proteasome inhibitor, IMiD, & CD38-targeting antibody (triple class refractory)?

Question Title

* 5. Which of the following points should be included when counseling a patient planning to receive teclistamab?

Question Title

* 6. 71 year old female diagnosed w/ IgG MM w/ t(4;14). She received 4 prior tx including daratumumab, lenalidomide, bortezomib, pomalidomide, carfilzomib & isatuximab. She lives 20 miles from cancer center but does not have a caregiver able to travel to cellular therapy center w/ her. Which treatment is best for her?

Question Title

* 7. JD is a 56-YOM dx w/ IgM MM w/ t(11;14). He received 5 prior regimens & is considered triple class refractory (but has not had carfilzomib or pomalidomide). He is a schoolteacher w/ the summer off but would like to avoid infusions during the school year.  Which treatment is best?

Question Title

* 8. Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity) 

( Privacy & Cookie Notice

T